Context Capital Management’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Context Capital Management’s Portfolio ORIAU Stock Details ORIAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-105,800	Closed	-$1.04M	–	827
2021 Q4	$1.04M	Hold	105,800	–	–	0.08%	280
2021 Q3	$1.05M	Buy	105,800 +5,800	+6%	+$57.9K	0.11%	211
2021 Q2	$1M	Buy	+100,000	New	+$1.01M	0.09%	231

Other funds holding ORIAU

JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Context Capital Management's ORIAU Position: Q1 2022 in Review

Context Capital Management sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q1 2022, closing a stake of 105,800 shares — an estimated $1.04M sold.

Context Capital Management first reported a position in ORIAU in Q2 2021 and held it in 3 quarters. The position peaked at $1.05M in Q3 2021. 14 funds tracked by Wall St. Rank hold ORIAU as of Q1 2022.

Context Capital Management reported no remaining Orion Biotech Opportunities Corp. Units position as of Q1 2022 after selling out during the quarter.
Context Capital Management sold 105,800 Orion Biotech Opportunities Corp. Units shares in Q1 2022, an estimated $1.04M.
Context Capital Management first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 3 quarters.
Context Capital Management's Orion Biotech Opportunities Corp. Units position peaked at $1.05M in Q3 2021.
14 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q1 2022.

Based on Context Capital Management's 13F filing for Q1 2022, filed 9 May 2022.